ClinicalTrials.gg
Not yet recruitingNCT07727252EARLY-PAUpdated Jul 27, 2026

Early Aldo Blockade in Subclinical PA

A Phase 2/3 interventional study of Eplerenone and Placebo in Subclinical Primary Aldosteronism, sponsored by Xinjiang Medical University. Not yet recruiting. Open to participants aged 30 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by Xinjiang Medical University · Phase 2/3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
880
Allocation
Randomized
Ages
30 Years to 55 Years
Sex
All
01

Study summary

This trial aims to evaluate the preventive effect of early intervention with eplerenone, a highly selective nonsteroidal mineralocorticoid receptor antagonist, against new-onset hypertension in normotensive patients with subclinical primary aldosteronism (PA), as well as its cardiorenal target organ protective effects and long-term safety profile.

The trial will be conducted across 15 to 20 tertiary hospitals nationwide with established expertise in PA diagnosis and management. A total of 880 eligible patients aged 30 to 55 years with normal blood pressure and biochemically/functionally confirmed subclinical PA will be enrolled and randomly assigned to the eplerenone group or the placebo group at a 1:1 ratio. The eplerenone group will receive a dose titration regimen with a target maintenance dose of 50 mg once daily orally, while the placebo group will follow a matched sham titration protocol. The double-blind treatment period will last 3 years, with an extension to 5 years permitted based on interim analysis findings.

The primary endpoint is the incidence of new-onset hypertension within 3 years, adjudicated blindly by an independent Clinical Endpoint Committee (CEC). Secondary endpoints include alterations in biomarkers of cardiorenal target organ damage, improvements in endocrine parameters, changes in adrenal nodule volume, and patient-reported outcomes. Safety endpoints cover the incidence of adverse events such as hyperkalemia, acute kidney injury, and hypotension.

This trial will fill a critical gap in evidence-based medicine regarding early intervention for subclinical PA for the first time. Its findings are expected to revise international clinical practice guidelines for PA and deliver a novel precision intervention strategy for the primary prevention of hypertension.

02

Conditions studied

  • Subclinical Primary Aldosteronism

Browse trials for

03

In context

Hyperaldosteronism

201 studies on the registry are indexed under Hyperaldosteronism; 91 are open to participants now.

This study's planned enrollment of 880 is above the median of 63 across 94 interventional studies indexed under Hyperaldosteronism.

Browse Hyperaldosteronism studies →

Lead sponsor

Xinjiang Medical University is the lead sponsor of 21 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 30 to 55 years old (inclusive), both genders.
  • (BMI) 18.5 to 35.0 kg/m² (inclusive).
  • Office blood pressure \< 140/90 mmHg, and no use of any antihypertensive drugs. Office blood pressure is measured at 3 visits with 1-week intervals. Patients rest in a seated position for 5 minutes before measurement, measured -times per visit, and the average of the 3 visits must meet the criteria.
  • Serum potassium in the low-normal or normal range.
  • Meeting diagnostic criteria: (A) ARR ≥ 2.52 ng/dL per pg/mL (chemiluminescence immunoassay), and PAC ≥ 6 ng/dL (blood sample required in the morning, fasting, after resting in a seated position for 30 minutes); OR (B) Renin ≤ 4.0 pg/mL; OR (C) Positive confirmatory test: Saline infusion test (SIT): PAC > 6 ng/dL after 4 hours of isotonic saline infusion; OR Captopril challenge test (CCT): PAC suppression rate \< 30% at 2 hours after oral administration of 50mg captopril.
  • Adrenal thin-slice CT showing unilateral adrenal nodule (\<15 mm in diameter), bilateral adrenal micronodules (\<10 mm in diameter), or negative findings.

Exclusion criteria

Exclusion Criteria:

  • History of diagnosed hypertension, including office BP ≥ 140/90 mmHg, previous use of antihypertensive drugs, or previous ABPM meeting hypertension diagnostic criteria.
  • Other etiologies of secondary hypertension, including renal artery stenosis, pheochromocytoma, Cushing's syndrome, thyroid dysfunction, -remediable aldosteronism, etc.
  • Severe renal insufficiency: \< 45 mL/min/1.73m² (CKD-EPI formula), or UACR > 300 mg/g.
  • Abnormal baseline serum potassium: serum potassium > 5.0 mmol/L, or serum potassium \< 3.0 mmol/L.
  • Severe hepatic insufficiency: Class C, or /AST > 3 times the (ULN).
  • History of allergy to eplerenone or any of the study drug.
  • Pregnant, lactating women, or subjects planning to become pregnant during the study period.
  • History of adrenal surgery.
  • Severe cardiovascular diseases, including (NYHA) Class IV heart failure, previous myocardial infarction, cerebral infarction, (TIA), severe arrhythmia, etc.
  • Severe comorbidities with an expected of \<5 years, including malignant tumors, severe diseases, end-stage organ failure, etc.
  • Use of drugs that cannot be discontinued prior to enrollment: strong inhibitors (ketoconazole, itraconazole, clarithromycin, nefazodone, etc.); strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's wort, etc.); other MRAs, potassium-sparing diuretics (amiloride, triamterene), potassium supplements; systemic glucocorticoids (except physiological replacement), licorice preparations; long-term high-dose NSAIDs.
  • History of drug abuse, alcohol dependence, or psychiatric illness that may affect study completion, as judged by the investigator.
  • Participation in other clinical trials or use of other drugs within 3 months prior to enrollment.
  • Any other conditions that, in the opinion of the investigator, may affect subject safety, trial compliance, or outcome assessment.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
880 participants (estimated)

Study arms

  • Placebo comparator
    Placebo Group

    Drug: Placebo

  • Experimental
    Eplerenone Group

    Drug: Eplerenone

Interventions

  • Eplerenone tablets, starting dose 25mg once daily orally. At Week 4 visit, titrate to 50mg once daily if serum potassium \<=4.5 mmol/L and eGFR decrease from baseline \<30%; maintain 25mg once daily if serum potassium 4.6-5.0 mmol/L; hold drug if potassium \>5.0 mmol/L or eGFR decrease \>=30%. At Week 8 visit, maintain the stable titrated dose for continuation until the end of the study. Long-term dose adjustment during follow-up will be performed according to the specific protocol Table 1 if potassium/eGFR abnormalities occur.

  • DrugPlacebo

    Placebo tablets completely matching the appearance, specifications, smell, and packaging of Eplerenone tablets, with no pharmacological activity. A sham titration scheme is adopted that is completely consistent with the Eplerenone group (including dose adjustment processes and follow-up monitoring) to strictly maintain the double-blind design.

06

What researchers measure

Primary outcomes

  1. Incidence of New-Onset Hypertension

    Time frame: Up to 36 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Aug 2029, 36 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2026
First posted
Jul 27, 2026
StartEst.
Aug 1, 2026
Primary completionEst.
Aug 1, 2029
CompletionEst.
Aug 1, 2029
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07727252
Lead sponsor
Xinjiang Medical University
Responsible party
Xiang Xie (Chief Physician, Xinjiang Medical University) — Principal investigator
First posted
Jul 27, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
Aug 1, 2029 (estimated)
Completion
Aug 1, 2029 (estimated)
Last update
Jul 27, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eplerenone

Start the discussion